Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
Healthcare
$3.95 +2.36%
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
52W Low $3.35High $17.94
Volume 1.32M
Average 0.18M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$54.17M
FY 2025 · Annual
Investing Cash Flow
-$49.67M
FY 2025 · Annual
Financing Cash Flow
$89.25M
FY 2025 · Annual
+8.9% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Depreciation & Amortization | 110K | 97K | 16K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 412K | 313K | 439K | 3.95M |
| Change in Working Capital | (1.31M) | (81K) | 1.57M | 356K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 31K | 776K | 798K | 239K |
| Other Working Capital | (1.34M) | (857K) | 775K | 117K |
| Other Non-Cash Items | 3.81M | 1.06M | 473K | 421K |
| Operating Cash Flow | (10.54M) | (5.82M) | (18.09M) | (54.17M) |
| Capital Expenditures | 0 | 0 | (109K) | (95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (11.89M) | (129.6M) |
| Sales of Investments | 0 | 0 | 0 | 80.03M |
| Other Investing Activities | (1M) | 0 | 0 | 0 |
| Investing Cash Flow | (1M) | 0 | (12M) | (49.67M) |
| Debt Repayment | (1M) | 0 | 0 | 0 |
| Common Stock Issued | 225K | 0 | 332K | 89.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1M | 0 | (3.34M) | 0 |
| Financing Cash Flow | 225K | 0 | 81.99M | 89.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.32M) | (5.82M) | 51.91M | (14.59M) |
| Free Cash Flow | (10.54M) | (5.82M) | (18.2M) | (54.27M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$57.6M
+ D&A-$1.3M
+ Stock-Based Comp$3.9M
+ Deferred Tax$0
+ Working Capital$356.0K
+ Other Non-Cash$421.0K
= Operating Cash Flow-$54.2M
- Capex-$95.0K
= Free Cash Flow-$54.3M
Analysis
FY2025 free cash flow is -$54.3M. FCF conversion is 94.2% of net income. Operating cash flow was -$54.2M, with capex of -$95.0K. The largest bridge item is Stock-Based Comp at $3.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| 8-K | Current report | Oct 8, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 8, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 |
Does AARD generate free cash flow?
Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$54.27M of free cash flow in fiscal 2025.
How much operating cash flow does AARD produce?
Operating cash flow was -$54.17M, before capital expenditures of $95,000.00.
Continue the stock analysis
Jump to another research area for this company.